Peptides and Senolytics: Which Anti-Age Ingredients Will Dominate the Haircare Market in 2026
Scientific labs are experimenting with "rejuvenating" hair formulas: NAD+, Wnt pathway activators, and senolytic peptides that destroy old cells are trending. Current products popularize proteins and proteomics for strengthening hair structure.
The Gist: What's Really Happening
The anti-age haircare market is moving from a phase of "promises" to a phase of "evidence-based biology." NAD+, Wnt pathway activators, and senolytic peptides are not marketing buzzwords. They are specific molecular mechanisms that are currently being patented, tested, and brought to market. In-Cosmetics Global 2026 in Paris, which gathered 14,000 professionals and 250 new ingredients, showed that ingredient suppliers are no longer working with the vague concept of "anti-age" but with specific hallmarks of aging—epigenetic changes, cellular senescence, mitochondrial dysfunction.
The real news is not that "peptides are trending." The real news is the formation of hair longevity as an independent scientific-commercial category that will completely redefine haircare shelves at Sephora and Ulta within the next 18 months.
Timeline and Context
February 2026. South Korea's JW Pharmaceutical receives approval for Phase I clinical trials of JW0061—a first-in-class Wnt pathway activator for hair growth. The patent has already been registered in 9 countries.
March 2026. LG Life Sciences (LG Household & Health Care) files patent application CN121622482A for a composition that prevents hair loss via the Wnt/β-catenin signaling pathway.
April 8, 2026. K18 announces its presentation at In-Cosmetics Global—topic: "Next-generation hair biology, aging pathways and molecular repair." K18 declares the start of research on follicle longevity.
April 14-16, 2026. In-Cosmetics Global 2026 in Paris. Mibelle Biochemistry presents PhytoSpherix Hair—a plant glycogen to nourish follicles. LipoTrue launches Keraduo—a fusion protein of keratin 31 and collagen XVII, claiming a 43.8% reduction in hair loss in 28 days.
April 2026. Results of the UMIN clinical study (UMIN000055442) are published: oral NMN improves hair quality in middle-aged women. Full data in Cosmetics, 2025, 12(5), 204.
May 9, 2026. We are here. The market is at a tipping point: old "anti-hair loss" formulas are rapidly becoming obsolete.
Who Wins and Who Loses
Winners:
- K18 / Unilever. Unilever keeps its finger on the pulse of hair biology through K18. When follicle longevity becomes mainstream, they will already have patents on molecular repair.
- Mibelle Biochemistry. EpiSnow and PhytoSpherix Hair position the company as the leading supplier of "longevity" ingredients for skin and hair.
- LipoTrue. Keraduo is the first commercial fusion protein combining keratin and collagen XVII in a single molecule. The company has created a new niche: biomimetic hair proteins.
- JW Pharmaceutical. If JW0061 passes clinical trials, it will be the first approved drug directly activating the Wnt pathway in hair follicles. Potential capitalization—billions of USD.
- LG Life Sciences. The 2026 patent application is insurance for the Asian market, where hair loss is one of the most commercially significant categories.
Losers:
- Traditional "anti-hair loss" shampoos with caffeine and biotin. Their era is ending. Consumers will demand NAD+ and Wnt activators, not "vitamins for hair."
- Brands without scientific expertise. When K18 talks about aging pathways and Mibelle about epigenetic modulation, brands without labs and patents have nothing to offer.
- Cosmetic NMN without proven efficacy. The study by Fujimoto T. et al. shows that NMN does not increase hair density—only growth rate and shaft quality. Manufacturers of "NMN for thickness" lose their scientific foundation.
What the Media Isn't Saying
1. Wnt activators are pharma, not cosmetics. Their path to the shelf will take years.
Most articles about "Wnt pathway in haircare" omit a crucial nuance: Wnt/β-catenin is a signaling pathway associated with oncogenesis. That's why JW0061 goes through IND regulation as a drug, not a cosmetic. No cosmetic brand can legally claim "activates Wnt" without pharmaceutical approval. This restriction will remain at least until 2029.
2. NMN works only in the absence of fatigue—and that's a bomb for marketing.
The most important finding from Fujimoto T.'s study at AAD 2026: NMN efficacy radically depends on fatigue levels. In the low-fatigue group, marked improvement in hair quality. In the high-fatigue group, minimal effect, density even decreases. This means the target audience for NMN haircare is not "everyone over 40" but "well-rested people over 40." Marketing built on "take a pill—get hair" won't work for chronically fatigued consumers.
3. Keraduo is a Trojan horse for collagen haircare.
LipoTrue chose collagen XVII—the one responsible for anchoring the follicle. Keraduo shows a 43.8% reduction in hair loss in 28 days, and 96% notice strengthening. This changes the game: previously, collagen in haircare was considered useless (molecules too large to penetrate); now fusion proteins solve this problem at an engineering level.
4. LG Life Sciences patents "plant extracts + Wnt"—opening a loophole for cosmetics.
Patent CN121622482A describes a composition that activates Wnt/β-catenin but is formulated as a "composition for preventing hair loss"—without reference to drug regulation. LG finds a workaround: using Wnt activity from plant components that can be registered as cosmetics.
Forecast: Next 30 Days and 90 Days
30 days (until June 8, 2026)
K18 will launch a public campaign around "follicle longevity"—first social media posts and collaborations with dermatologists explaining that the follicle ages like skin. LipoTrue will start sending Keraduo samples to beauty editors—expect reviews with headlines like "the protein that stopped my hair loss." Mibelle Biochemistry will announce the first commercial partnership for PhytoSpherix Hair with a D2C brand from the US or Korea.
90 days (until August 7, 2026)
JW Pharmaceutical will begin recruiting 104 volunteers for Phase I of JW0061 at Seoul National University—first data leaks expected by the end of the phase. LG Life Sciences will register the "Wnt composition" in several Asian jurisdictions as a cosmetic product. The first independent review comparing "NAD+ haircare vs Wnt haircare vs Senolytic haircare" will appear in an industry publication. Sephora and Ulta will start discussions about creating a separate "Hair Longevity" shelf category. And most importantly—by August it will become clear: anti-age haircare has finally split into "evidence-based" (patents, clinical studies) and "decorative" (fragrant oils and promises). The second segment will begin to rapidly lose market share.
— Editorial Team
